Baha ZENGEL, AHMET ALACACIOĞLU, Ayşe YAĞCI, Hakan POSTACI, Özgür KAVAK, Galip Ali DENECLI, Erhan GÖKMEN

Pathological complete response after imatinib mesylate therapy in ınoperabl gastrointestinal stromal tumor: A case report

Gastrointestinal stromal tümörler CD34 and c-kit (CD117) ekspresyonu ile karekterize olan, gastrointestinal sistemin en sık görülen mezenkimal maligniteleridir. İmatinib mesiat, transmembran reseptör c-kit ürünlerini baskılayan küçük molekül tirozin kinaz inhibitörüdür. Metastatik ve inope- rabl gastarointestinal stromal tümörlerde yapılan klinik çalışmalarda imatinib mesilat tedavisi ile parsiyel yanıt oranları 40% ile 69% arasındadır. Fakat tam yanıt nadirdir. Bu yazımızda 46 yaşında anrezektabl gastrointestinal stromal tümorlü erkek hastada, imatinib mesilat tedavisi ile sağlanan patolojik tam yanıt değerlendirilmiştir.

Inoperabl gastrointestinal tümörde ımatinib mesilat tedavisi sonrası patolojik tam yanıt: olgu sunumu

Gastrointestinal stromal tumors are characterized by the expression of CD34 and c-kit (CD117) and represent the most common mesenchymal malig- nancy of the gastrointestinal tract. Imatinib mesylate is small molecule tyrosine kinase inhibitor that suppresses transmembrane receptor c-kit pro- ducts. Clinical studies for metastatic and inoperabl GISTs have demonstrated partial response rate ranging from 40% to 69% in patients treated with imatinib mesylate. But complete response is rare. We present a 46 year old man patient with unresectable gastrointestinal stromal tumor that has histopatologically proven complete response to imatinib mesylate therapy.

PDF

___

1.Demetri GD. Gastrointestinal stromal tumor. In: Cancer: Prin- ciples and practice of oncology, 8th ed, DeVita VT, Hellman S, Rosenberg SA (Eds), p 1257,Lippincott-Williams &Wilkins, Philadelphia, 2008.
2.Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-519.
3.Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointes- tinal stromal tumors show phenotypic characteristic of the in- tersititial cell of Cajal. Am J Pathol 1998; 152: 1259-1269.
4.Chiang KC, Chen TW, Yeh CN, Liu FY, Lee HL, Jan YY. Advanced gastrointestinal stromal tumor patients with comple- te response after treatment with imatinib mesylate. World J Gastroenterol 2006; 12: 2060-2064.
5.Melichar B, Voboril Z, Nozicka J, et al. Pathological complete response in advanced gastrointestinal stromal tumor after ima- tinib therapy. Internal Medicine 2005; 44: 1163-1168.
6.Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Eng J Med 2001; 344: 1052- 1056.
7.Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007; 14: 14-24.
8.Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disea- se following molecular-targeted therapy with imatinib mesyla- te in advanced/metastatic GIST. Ann Surg 2007; 245: 341- 346.
9.Nishida T, Shirao K, Sawaki A, et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 2008; 13: 244-251.
10.Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Patho- logic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006; 32: 961-963.
11.Salazar M, Barata A, André S, et al. First reportof a complete pathological response of a pelvic GIST treatedwith imatinib as neoadjuvant therapy.Gut. 2006; 55: 585-586.
12.Suzuki S, Sasajima K, Miyamoto M, et al. Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate. World J Gastroenterol 2008; 14: 3763-3767.